Evidence map›Paper›PMID 41281473›Full record

ArticleWorld journal of gastrointestinal oncology2025

Meta-analysis of the efficacy of neoadjuvant immunotherapy combined with radiotherapy and chemotherapy for locally advanced rectal cancer.

Wen-Xing Yan, Hong-Qin Yuan, Ze-Yi Xiong, Li-Juan Qin, Juan Wu, Juan He, Jie Mu, Jia Li, Ning Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wen-Xing YanDepartment of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China.
Hong-Qin YuanDepartment of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China.
Ze-Yi XiongDepartment of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China.
Li-Juan QinDepartment of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China.
Juan WuDepartment of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China.
Juan HeDepartment of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China.
Jie MuDepartment of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China.
Jia LiDepartment of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China.
Ning LiDepartment of Radiation Oncology, Shanxi Province Cancer Hospital Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, Shanxi Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapy is an approved treatment for metastatic rectal cancer in patients with defective mismatch repair (MMR).

aimTo examine the clinical efficacy of neoadjuvant immunotherapy combined with radiotherapy and chemotherapy for the treatment of locally advanced rectal cancer (LARC), with a focus on patients with proficient MMR (pMMR) and microsatellite stability.

methodsTwo researchers searched multiple databases for publications up to September 2024. All included publications examined neoadjuvant immunotherapy for LARC, and reported major pathological response (MPR), pathological complete response (pCR), clinical complete response (CCR), and rates of R0 resection and anus-preserving surgery. Meta-analysis, subgroup analysis, sensitivity analysis, and analysis of publication bias were performed.

resultsWe included 15 publications (796 patients). The MPR, pCR, and CCR were significantly better in the group that received immunotherapy (all

conclusionThe addition of neoadjuvant immunotherapy improved the clinical remission rate of patients who had LARC with pMMR, and the treatment-related adverse reactions were generally acceptable. Neoadjuvant immunotherapy combined with radiotherapy and chemotherapy should be considered for patients with LARC.

Indexed as

Defective mismatch repairImmunotherapyLocally advanced rectal cancerMeta-analysisMicrosatellite stabilityProficient mismatch repair

Identifiers

PMID41281473
PMCPMC12635701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.